key: cord-0719194-mp2wpvaj
authors: Wadoo, Ovais; Karim, Mustafa Abdul; ElTorki, Yassin; Riaz, Sadaf; Latoo, Javed; Alabdulla, Majid
title: Clozapine Prescribing and Safety During COVID-19
date: 2021-04-10
journal: Asian J Psychiatr
DOI: 10.1016/j.ajp.2021.102658
sha: cf3fe201d70b6e4a135dd60413743e2a718a0747
doc_id: 719194
cord_uid: mp2wpvaj

nan

frequency of Absolute Neutrophil Count (ANC) testing to once every 3 months for patients who had been on clozapine for more than one year with no previous record of neutropenia (Siskind et al., 2020) . We aimed to evaluate the trend of clozapine prescriptions during the COVID-19 pandemic in Qatar. Our secondary objectives were to evaluate the rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection among patients on clozapine;

rates of neutropenia and related medical complications; clozapine toxicity; psychiatric and medical admissions during this period and whether these variables were associated with revised clozapine dispensation and blood monitoring.

The study design was a retrospective case-note review. The study received approval from the HMC Institutional Review Board (MRC-01-20-931). All patients maintained on clozapine were included in the study. During the study period (March 2020 -September 2020), 95 patients were registered out of which 25 were being managed in the inpatient settings and 70 in the community setting.

Published studies and commentators have drawn attention to the concern that the pandemic may have a disproportionate impact on patients maintained on clozapine. Table 1 shows the sociodemographic and clinical characteristics and pattern of clozapine dispensation and monitoring details of our sample. Patients were mainly Qatari nationals followed by non-Qatari Arabs. The mean age was 36 years and the majority were males. Most patients were diagnosed with schizophrenia and under the care of outpatient mental health services. The COVID-19 pandemic brought unique challenges to management of patients maintained on clozapine.

Clozapine was initiated only for one new patient during the study period. New clozapine initiations during COVID-19 pandemic had the potential to lead to diagnostic confusion due to J o u r n a l P r e -p r o o f overlap of COVID-19 symptoms and clozapine side-effects. It appears that the potential risk of initiating clozapine was deemed more than the benefits during the pandemic. Based on clozapine initiation date and blood results, 79 patients met the criteria for revised frequency of ANC testing as per TRRPG monitoring guidelines. Only 28 patients were put on revised monitoring schedule Patients on revised monitoring had no incidence of neutropenia and fewer admissions to psychiatric (1 (1.1%) vs 3 (3.2%)) and medical (1(1.1%) vs 3(3.2%)) facilities. It is not surprising that patients on revised monitoring had no incidence of neutropenia and fewer incidences of medical complications as they were a select group of stable patients maintained on clozapine for more than one year with no previous record of neutropenia. Two patients (2.1%) tested positive for SARS-Cov-2 PCR test in our study, lower than the 5% infection rate among the general population in Qatar at the time ("COVID19 Home," n.d.) . Both patients were in the revised guidelines group as they were stable patients maintained on clozapine for many years. Clozapine toxicity was suspected for one patient in the revised monitoring group. This was based solely on clinical suspicion as plasma level monitoring of clozapine is not available in our center.

In addition, psychiatric and medical admissions were not linked to clozapine-related complications or monitoring. Admissions to inpatient mental health services were largely due to relapse in the context of partial or poor compliance. The main reason for nonadherence was adverse effect intolerability.

In conclusion, patients maintained on clozapine were safely managed without any major medical complications. Revised monitoring did not adversely impact patients maintained on clozapine.

Despite its clinical superiority, clozapine continues to be underutilized. Prescriber, patient and Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. J o u r n a l P r e -p r o o f

Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories

Clozapine treated patients and COVID-19: Ensuring continued care through collaboration

Consensus statement on the use of clozapine during the COVID-19 pandemic